What is NTHI's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.09B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for NTHI?

P/E (TTM) is n/a and 52-week range is $2.50 to $12.00 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s NTHI figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for NTHI?

The company profile lists revenue (TTM) near $80K, net income (TTM) near -$3.91B, EPS (TTM) near -$1.86 when available from the market-data feed. Figures are informational and may lag live markets.

Where is NeOnc Technologies Holdings Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Calabasas, California, US, 28.8M shares outstanding, ISIN US64051A1016 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

NeOnc Technologies Holdings Inc

$NTHI

Health Care · Pharmaceuticals

Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Calabasas, California and currently employs 5 full-time employees. The company went IPO on 2025-03-26. The firm is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. The company is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company is developing novel drug delivery methods to be used in combination with novel drug candidates. The firm has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).

Employees

Website

neonc.com

IPO

2025-03-26

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US64051A1016

Headquarters

Calabasas, California, US

Shares outstanding

28.8M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

12.20%

Browse other companiesFree AI scores and summaries for more stocks